Novartis Ag (NVSEF) Cost of Revenue (2009 - 2025)

Novartis Ag (NVSEF) has 15 years of Cost of Revenue data on file, last reported at $3.3 billion in Q2 2025.

• Quarterly Cost of Revenue rose 4.7% year-over-year to $3.3 billion in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $19.1 billion (up 44.96% YoY) and the FY2025 annual result came in at $13.7 billion, up 6.8% from the prior year.
• Cost of Revenue eased to $3.3 billion in Q2 2025 per NVSEF's latest filing, from $6.3 billion in the prior quarter.
• The five-year high for Cost of Revenue was $6.3 billion in Q4 2023, with the low at $236.0 million in Q3 2022.
• Average Cost of Revenue over 5 years is $2.3 billion, with a median of $1.7 billion recorded in 2023.
• The widest YoY moves for Cost of Revenue: up 2403.16% in 2023, down 10.9% in 2023.
• Novartis Ag's Cost of Revenue stood at $238.0 million in 2021, then rose by 6.3% to $253.0 million in 2022, then soared by 2403.16% to $6.3 billion in 2023, then declined by 1.01% to $6.3 billion in 2024, then plunged by 47.01% to $3.3 billion in 2025.
• Business Quant data shows NVSEF's Cost of Revenue at $3.3 billion in Q2 2025, $6.3 billion in Q4 2024, and $3.2 billion in Q2 2024.